CNS activity of poziotinib in NSCLC with exon 20 insertion mutations.

被引：11

作者：

Le, Xiuning

Garassino, Marina Chiara

Cornelissen, Robin

Socinski, Mark A.

Tchekmedyian, Nishan

Molina, Julian R.

Baik, Christina S.

Leu, Sharon

Dreiling, Lyndah

Lebel, Francois M.

Clarke, Jeffrey Melson

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] IRCCS, Natl Canc Inst, Dept Med Oncol, Milan, Italy

[3] Erasmus MC, Rotterdam, Netherlands

[4] Advent Hlth Hematol & Oncol, Orlando, FL USA

[5] Pacif Shores Med Grp, Huntington Beach, CA USA

[6] Mayo Clin, Rochester, MN USA

[7] Seattle Canc Care Alliance, Seattle, WA USA

[8] Spectrum Pharmaceut, Irvine, CA USA

[9] Duke Univ, Med Ctr, Durham, NC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.9093

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9093

引用

页数：2

共 50 条

[41] Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC [J].

Angela Zupa ;

Giulia Vita ;

Matteo Landriscina ;

Luciana Possidente ;

Michele Aieta ;

Alfredo Tartarone ;

Giuseppina Improta .

Medical Oncology, 2012, 29 :3198-3201

[42] Clinicopathological Characteristics for NSCLC Harboring EGFR Exon 20 Insertion [J].

Morikawa, K. ;

Kakinuma, K. ;

Inoue, T. ;

Mineshita, M. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S496-S496

[43] Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC [J].

Zupa, Angela ;

Vita, Giulia ;

Landriscina, Matteo ;

Possidente, Luciana ;

Aieta, Michele ;

Tartarone, Alfredo ;

Improta, Giuseppina .

MEDICAL ONCOLOGY, 2012, 29 (05) :3198-3201

[44] Targeting exon 20 insertion mutations in lung cancer [J].

Yang, Yaning ;

Wang, Yan .

CURRENT OPINION IN ONCOLOGY, 2023, 35 (01) :37-45

[45] Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program [J].

Prelaj, A. ;

Bottiglieri, A. ;

Proto, C. ;

Lo Russo, G. ;

Signorelli, D. ;

Ferrara, R. ;

Galli, G. ;

De Toma, A. ;

Viscardi, G. ;

Brambilla, M. ;

Lobefaro, R. ;

Manglaviti, S. ;

Occhipinti, M. ;

Labianca, A. ;

Gallucci, R. ;

Molino, G. ;

Zilembo, N. ;

Greco, F. G. ;

Torri, V. ;

Garassino, M. C. .

ANNALS OF ONCOLOGY, 2020, 31 :S882-S882

[46] Poziotinib treatment in intractable NSCLC: Epidermal growth factor receptor and human epidermal growth factor receptor 2 exon 20 insertion mutation disease [J].

Rosell, Rafael ;

Zorrilla, Andres F. Cardona .

EUROPEAN JOURNAL OF CANCER, 2021, 149 :233-234

[47] Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal? [J].

Borm, Frank. J. ;

Smit, Egbert F. .

JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) :964-966

[48] Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison [J].

Ou, Sai-Hong I. ;

Lin, Huamao M. ;

Hong, Jin-Liern ;

Yin, Yu ;

Jin, Shu ;

Lin, Jianchang ;

Mehta, Minal ;

Zhang, Pingkuan ;

Nguyen, Danny ;

Neal, Joel W. .

LUNG CANCER, 2023, 179

[49] Online CME Improves Clinicians' Ability to Identify and Manage Patients with NSCLC and EGFR Exon 20 Insertion Mutations [J].

Worst, M. A. ;

Small, A. ;

Kadkhoda, H. ;

Reid, K. ;

Cannon, M. ;

Furedy, A. ;

Sarris, A. ;

Hsiao, S. ;

Camidge, D. R. .

JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) :S457-S458

[50] Osimertinib (AZD9291) is effective against NSCLC cells harboring EGFR exon 20 insertion mutations [J].

Lee, Yusoo ;

Kim, Tae Min ;

Kim, Dong-Wan ;

Ahn, Yong-Oon ;

Kim, Soyeon ;

Keam, Bhumsuk ;

Kim, Miso ;

Heo, Dae Seog .

CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →